Estithmar Holding Reports an Exceptional 50% Surge in Net Profit to QAR 170 Million
Announcing Q1 2025 Financial Results
Estithmar Holding Q.P.S.C. announced a net profit of QAR 170 million for Q1 2025, reflecting a 50% increase compared to the same period last year. The company highlighted a 64% surge in revenue, reaching QAR 1.3 billion compared to QAR 797 million in Q1 2024. Gross profit rose to QAR 416 million, from QAR 196 million in Q1 2024. EBITDA reached QAR 273 million, marking a 53% increase. Earnings per share also grew by 57%, reaching QAR 0.047.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421669945/en/
Estithmar Holding Reports an Exceptional 50% Surge in Net Profit to QAR 170 Million (Infographic: AETOSWire)
These strong financial indicators reflect the efficiency of Estithmar Holding’s investment strategy. International projects previously announced by Estithmar Holding started to have a tangible impact on its financial performance in revenue, profits and assets.
The results reflect the achievement of a strategic objective: a balanced contribution to profits and revenues from all four Clusters—Healthcare, Services, Tourism & Real Estate Development, and Contracting & Industries.
The Healthcare cluster posted significant growth in Q1 2025 driven by the cluster’s hospitals outside Qatar which contributed to revenue as new income streams, including Imam Al-Hassan Al-Mujtaba Hospital in Karbala, Al-Nasiriyah Teaching Hospital in Dhi Qar, Iraq, and Misrata Heart & Vascular Center in Libya. Moreover, the growing number of Hospitals outside Qatar in Iraq, Algeria and Libya reflects the confidence that governments across the MENA region have placed in the quality of services provided by Apex Health, the healthcare subsidiary of Estithmar Holding.
The Services cluster maintained leadership in Qatar, especially in Facilities Management and Catering. Expansion into KSA, Jordan and Iraq also significantly contributed to the Cluster’s profitability and the development of new income streams.
The Tourism & Real Estate Development cluster stayed on track with project delivery, including Rixos Baghdad (Iraq) and Rosewood Maldives Resort, driving a QAR 600 million increase in company assets in Q1 2025. Additionally, enhanced efficiency boosted profitability in existing projects, Lusail Winter Wonderland and Al Maha Island.
The Contracting & Industries cluster also made a notable contribution to revenue and profit growth, especially at the peak phase of project deliveries in the Kingdom of Saudi Arabia, including major projects such as the Red Sea Airport and the Yacht Club. The Cluster also secured new projects with Saudi PIF companies and improved local operational efficiency, enhancing profitability in Qatar.
Overall, Estithmar Holding’s Q1 2025 results highlight sustained growth aligned with its strategy to increase shareholder value on the short and the long term.
Group CEO Mr. Juan Leon stated:
“The exceptional rise in all financial indicators reflects the dedication of Estithmar’s team, and I look forward to working closely with them to build on Estithmar Holding’s growth story in Qatar and abroad. Analyzing these results, Estithmar Holding has demonstrated the ability to deliver sustained, diversified growth—both vertically and horizontally—paving the way for further expansion as investor confidence strengthens and our footprint continues to grow both locally and internationally.”
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421669945/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting22.4.2025 10:37:00 CEST | Press release
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual Meeting (AACR) 2025 being held in Chicago April 25-30, 2025. In the poster, entitled “Preferential tumor uptake and retention of EGL-001, an anti-CTLA4-IL2 mutein fusion antibody achieving selective tumor Treg depletion”. Egle Therapeutics unveils preclinical biodistribution data on EGL-001, a novel anti-CTLA4-IL2 mutein fusion antibody designed to selectively deplete tumor-infiltrating regulatory T cells (Tregs). EGL-001 mode of action combines competitive inhibition of IL-2 signaling and potent downregulation of surface CD25, leading to induction of Treg apoptosis. In vivo EGL-001 preferentially bound to the surface of Tregs due to their high CTLA-4 and CD25 expression and depleted them from the tumor microenvironment without affecting other immun
The Smarter E Europe: Launch of Special Exhibit on Bidirectional Charging – the Energy Transition Gains Traction22.4.2025 09:00:00 CEST | Press release
Electricity from renewable sources has become the new normal – in Germany alone, around 60 percent of net electricity generation came from renewables in 2024. But the growing volume of green power is posing new challenges for energy supply: The integration into the existing system urgently requires more flexibility. A Euroelectric/EY study forecasts a doubling of daily European flexibility demand by 2030 compared to 2021, potentially reaching 1.8 TWh daily (137 TWh annually), a substantial rise from the prior 1.5 TWh weekly demand. Electric vehicle (EV) batteries are identified as a key flexibility solution, potentially offering around 116 TWh capacity within five years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417476684/en/ A special exhibition at The smarter E Europe is dedicated to bidirectional charging. ©Solar Promotion GmbH Dr. Frank Spennemann, Senior Manager Charging Solutions Energy at Mercedes-Benz, has a
A new weapon in the global fight against malaria22.4.2025 09:00:00 CEST | Press release
World Health Organization prequalifies Syngenta’s innovative insecticide Sovrenta® Malaria is one of the world’s most deadly diseases, and it is becoming more pervasive – despite decades of effort and some successes on the path to eradicating it. According to the World Health Organization (WHO), malaria infected 263 million people and killed nearly 600,000 people in 2023 – 75% of whom were children under the age of 5. Of those afflicted, 94% are in Africa – where malaria crushes communities and can cripple economies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422328472/en/ Syngenta Vector Control: A leading role in the prevention of vector-borne disease transmission through its portfolio of mosquito control products Spread by parasites in infected mosquitoes that are highly adept at evolving, malaria’s rise reflects the reality of insecticide resistance and the difficulties developing new solutions. The effective cont
IFF Pharma Solutions to Showcase Plant-Based Dietary Supplement Ingredients and Technical Expertise at Vitafoods™ Europe 202522.4.2025 08:00:00 CEST | Press release
Improving the World of Dietary Supplements with a Breadth of Proven Brands. IFF (NYSE: IFF) Pharma Solutions is excited to announce its participation at Vitafoods™ Europe 2025, the premier global nutraceutical event. The team will showcase its cutting-edge dietary supplement plant-based ingredients portfolio of innovative and trusted brands including SeaGel®, VERDIGEL™ SC, GRINDSTED® Pectin Premium, Ac-Di-Sol®, Avicel®, Accelerate®, and METHOCEL™ in hall 4 at booth 4F25, May 20-22, at the Fira Barcelona Gran Via. "We are excited to highlight vivid examples of how our high-quality functional ingredients and technical expertise help our customers produce superior supplements," said Firat Nalbantoglu, EMEA commercial leader, IFF Pharma Solutions. "Our technical and commercial experts look forward to offering solutions for formulation and processing challenges. If you aim to enhance efficacy and bioavailability in your dietary supplements, we invite you to discover new possibilities with u
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay22.4.2025 06:15:00 CEST | Press release
Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM’s ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes. Following a rigorous review by the Clinical Laboratory Evaluation Program (CLEP), the Department of Health has determined that LabPMM meets the required standards and granted approval to offer the FLT3 ITD MRD Assay in New York State. This approval underscores the assay’s robust analytical performance and clinical utility in the detection of MRD in patients with FLT3 ITD-mutated AML. "This milestone reflects our commitment to improve patient lives with precision diagnostics," said Jordan Thornes, V.P. Global Clinical Opera
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom